quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 13, 2026

CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP

View original at seekingalpha.com
CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP Earnings Call Insights: CareTrust REIT (CTRE) Q4 2025 MANAGEMENT VIEW * David Sedgwick, CEO, described 2025 as a “transformational year” for CareTrust, highlighting a record pace of investments and the company’s expansion into the U.K…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • CareTrust doubled its team of professionals in 2025 and brought in-house capabilities like tax and data science

    80% confidence

  • The difference for continued strong growth is that the team is deeper and more capable, and they have the U.K. and SHOP TAMs to play in as well

    80% confidence

  • The $500 million pipeline is about half U.K. care homes, about one-third U.S. skilled nursing, and the rest is a combination of SHOP deal, triple-net seniors and a couple of small loans

    80% confidence

  • The skilled nursing environment is in a really good place right now with labor in a much better place than recent history

    80% confidence

  • The start of 2026 feels very much like deja vu all over again compared to the beginning of 2025

    80% confidence

  • Data analytics team is prioritized on building out SHOP capabilities but will ultimately impact the whole organization

    80% confidence

  • Q4 normalized FFO increased 42.7% year-over-year to $104.1 million and normalized FAD increased 38.7% to $103 million

    80% confidence

  • SHOP deals are heavily marketed and the company targets a low double-digit IRR

    80% confidence

  • With great operators and beefy coverage, CareTrust can manage through any headwinds in skilled nursing

    80% confidence

  • Investment pipeline remains strong at approximately $500 million

    80% confidence

  • Q4 investments totaled approximately $562 million with a blended stabilized yield of 8.8%

    80% confidence

  • Most competition is seen in SHOP where cap rates continue to compress as investors seek more exposure

    80% confidence

  • 2025 was a transformational year for CareTrust with record pace of investments and expansion into U.K. care home market and U.S. SHOP

    80% confidence

  • 2026 guidance does not assume any new investments, dispositions, debt repayments, or equity issuances beyond those announced to date

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
CareTrust outlines 9.4% FFO growth target for 2026 while expanding in U.K. and SHOP — Source | Via News | pt.VIA.NEWS